

TABLE OF CONTENTS	PAGE
1.0 INTRODUCTION .....	4
2.0 STUDY OBJECTIVES .....	6
3.0 INSTITUTIONAL REVIEW BOARD .....	7
4.0 INFORMED CONSENT .....	7
5.0 STUDY POPULATION .....	7
5.1 Inclusion Criteria .....	7
5.2 Exclusion Criteria .....	7
6.0 STUDY PLAN .....	8
6.1 Design .....	8
6.2 Recordkeeping and Monitoring .....	9
6.3 Investigational Supplies .....	9
6.3.1 Study Drug Description .....	9
6.3.2 Packaging .....	9
6.3.3 Dosage Preparation .....	10
6.3.4 Dose Administration .....	11
6.3.5 Storage Requirements .....	11
6.3.6 Study Drug Accountability .....	11
6.3.7 Retrieval and Destruction .....	11
6.4 Randomization and Blinding .....	11
6.5 Methods .....	12
6.5.1 Screening Visit #1 (21 to 17 days before Day 0) .....	12
6.5.2 Screening Visit #2 (minimum 4 days after Screening Visit #1) .....	13
6.5.3 Day 0 (Randomization and Immunization) .....	13
6.5.4 Day 7 (± 3 days) .....	14
6.5.5 Day 42 (± 7 days) .....	15
6.5.6 Day 182 (± 14 days) .....	15
6.5.7 Day 378 (± 14 days) .....	15
6.5.8 Quarterly Visits after Day 378 (± 7 Days: Day 469, 560, 651, 743, 833, etc., until the study is closed.) .....	15
6.6 Laboratory Tests .....	15
6.6.1 Clinical Laboratory Evaluations .....	15
6.6.1.1 Serum Chemistry .....	15
6.6.1.2 Microbiology .....	16
6.6.2 Special Serologies (to be performed by Nabi-Rockville laboratory) .....	16
6.7 Study Measurements .....	16
6.7.1 Reactogenicity Assessment .....	16
6.7.2 Physical Examination .....	16
6.7.3 Measurement of Vital Signs .....	17

6.7.4 Bacteremia .....	17
6.7.5 Other Serious Bacterial Infections .....	17
7.0 ADVERSE EVENTS .....	18
7.1 Adverse Event Recording .....	18
7.2 Serious Adverse Events .....	19
8.0 ANALYSIS PLAN.....	20
8.1 Sample Size .....	20
8.2 Efficacy Analysis .....	22
8.3 Assessing Variation Among Study Sites .....	23
8.4 Description of S. aureus type 5 and type 8 CPS specific Antibody Levels .....	24
8.5 Serologic correlates of protection .....	24
8.6 Interim Analysis .....	25
8.7 Safety Analyses .....	25
9.0 WITHDRAWAL FROM STUDY.....	26
10.0 AGREEMENT WITH PROTOCOL.....	27
11.0 REFERENCES .....	28
APPENDIX A - TIME AND EVENTS SCHEDULE.....	31
APPENDIX B - KARNOFSKY PERFORMANCE SCALE .....	32
APPENDIX C - METHOD FOR NASAL CULTURE .....	33
APPENDIX D - VACCINE REACTOGENICITY DEFINITIONS AND REACTOGENICITY WORKSHEET.....	34
APPENDIX E - HOW TO TAKE YOUR TEMPERATURE .....	35

## 6.0 STUDY PLAN

### 6.1 Design

This is a Phase III, multicenter, prospective, randomized, stratified, placebo-controlled, double-blind clinical trial

The subjects at each site will be randomized at a 1:1 ratio to one of two treatment regimens ( *S aureus* vaccine or an inactive placebo)

After injection, subjects will be observed for vaccine immunogenicity (serum *S. aureus* types 5 and 8-specific IgG) and occurrence of all culture-proven *S. aureus* infections and all culture-proven *S. aureus* bacteremias until the study is closed.

active elicitation of adverse events by history and physical examination, with assessment of seriousness and relationship to the study drug, will be carried out by the sub-investigators.

#### **6.4 *Randomization and Blinding***

Subjects will be randomized to the two treatment groups in a 1:1 ratio.

Identical-appearing vaccine and phosphate-buffered saline placebo vials will receive blinded labeling, with each vial bearing a unique numeric code.

The assignment of unique numeric codes to active vaccine or placebo will be securely retained until such times as designated by the analysis plan (section 8.0).